A systems model of Parkinson’s disease using biochemical systems theory (Sasidharakurup et al. 2017)


Sasidharakurup H, Melethadathil N, Nair B, Diwakar S. (2017). A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. Omics : a journal of integrative biology. 21 [PubMed]

See more from authors: Sasidharakurup H · Melethadathil N · Nair B · Diwakar S

References and models cited by this paper

Atack CV. (1973). The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay. British journal of pharmacology. 48 [PubMed]

Baba M et al. (1998). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. The American journal of pathology. 152 [PubMed]

Beal MF. (1996). Mitochondria, free radicals, and neurodegeneration. Current opinion in neurobiology. 6 [PubMed]

Betarbet R et al. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature neuroscience. 3 [PubMed]

Braatz EM, Coleman RA. (2015). A mathematical model of insulin resistance in Parkinson's disease. Computational biology and chemistry. 56 [PubMed]

Bromek E, Haduch A, Gołembiowska K, Daniel WA. (2011). Cytochrome P450 mediates dopamine formation in the brain in vivo. Journal of neurochemistry. 118 [PubMed]

Burré J, Sharma M, Südhof TC. (2015). Definition of a molecular pathway mediating a-synuclein neurotoxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 35 [PubMed]

Cardoso SM, Moreira PI, Agostinho P, Pereira C, Oliveira CR. (2005). Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Current drug targets. CNS and neurological disorders. 4 [PubMed]

Cedillos RO. (2013). a-Synuclein aggregates activate the Nlrp3 inflammasome following vesicle rupture Master's Thesis, 1859. Loyola University. Chicago, IL.

Clayton DF, George JM. (1998). The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends in neurosciences. 21 [PubMed]

Conway KA, Harper JD, Lansbury PT. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature medicine. 4 [PubMed]

Eisenhofer G et al. (1997). Substantial production of dopamine in the human gastrointestinal tract. The Journal of clinical endocrinology and metabolism. 82 [PubMed]

Eliezer D, Kutluay E, Bussell R, Browne G. (2001). Conformational properties of alpha-synuclein in its free and lipid-associated states. Journal of molecular biology. 307 [PubMed]

Eriksen J, Jørgensen TN, Gether U. (2010). Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. Journal of neurochemistry. 113 [PubMed]

Fahn S. (2003). Description of Parkinson's disease as a clinical syndrome. Annals of the New York Academy of Sciences. 991 [PubMed]

Falkenburger BH, Schulz JB. (2006). Limitations of cellular models in Parkinson's disease research. Journal of neural transmission. Supplementum. [PubMed]

Farrer MJ. (2006). Genetics of Parkinson disease: paradigm shifts and future prospects. Nature reviews. Genetics. 7 [PubMed]

Fink AL. (1998). Protein aggregation: Folding aggregates, inclusion bodies and amyloid Fold Des. 3

GREENFIELD JG, BOSANQUET FD. (1953). The brain-stem lesions in Parkinsonism. Journal of neurology, neurosurgery, and psychiatry. 16 [PubMed]

Geddes JW. (2005). alpha-Synuclein: a potent inducer of tau pathology. Experimental neurology. 192 [PubMed]

Gendron TF, Petrucelli L. (2009). The role of tau in neurodegeneration. Molecular neurodegeneration. 4 [PubMed]

Giasson BI et al. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (New York, N.Y.). 300 [PubMed]

Hanger DP, Anderton BH, Noble W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in molecular medicine. 15 [PubMed]

Hiroi T, Imaoka S, Funae Y. (1998). Dopamine formation from tyramine by CYP2D6. Biochemical and biophysical research communications. 249 [PubMed]

Houghton D, Hurtig H. (2013). Parkinson's Disease: Medications.

Iljina M et al. (2016). Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proceedings of the National Academy of Sciences of the United States of America. 113 [PubMed]

Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. (2003). Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. Journal of neuropathology and experimental neurology. 62 [PubMed]

Kahle PJ, Haass C. (2004). How does parkin ligate ubiquitin to Parkinson's disease? EMBO reports. 5 [PubMed]

Kim WS, Kågedal K, Halliday GM. (2014). Alpha-synuclein biology in Lewy body diseases. Alzheimer's research & therapy. 6 [PubMed]

Kitano H, Matsuoka Y, Jouraku A, Funahashi A, Kikuchi N. (2006). Celldesigner: A modeling tool for biochemical networks Proceedings of the 38th Conference on Winter Simulation, Monterey, CA.

LIPKIN LE. (1959). Cytoplasmic inclusions in ganglion cells associated with parkinsonian states: a neurocellular change studied in 53 cases and 206 controls. The American journal of pathology. 35 [PubMed]

Lei P et al. (2010). Tau protein: relevance to Parkinson's disease. The international journal of biochemistry & cell biology. 42 [PubMed]

Levy OA, Malagelada C, Greene LA. (2009). Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis : an international journal on programmed cell death. 14 [PubMed]

Longo GS et al. (2015). Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients. Arquivos de neuro-psiquiatria. 73 [PubMed]

Lotharius J, Brundin P. (2002). Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nature reviews. Neuroscience. 3 [PubMed]

Marques O, Outeiro TF. (2012). Alpha-synuclein: from secretion to dysfunction and death. Cell death & disease. 3 [PubMed]

Masters JM, Noyce AJ, Warner TT, Giovannoni G, Proctor GB. (2015). Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism & related disorders. 21 [PubMed]

Meiser J, Weindl D, Hiller K. (2013). Complexity of dopamine metabolism. Cell communication and signaling : CCS. 11 [PubMed]

Mellick GD et al. (2009). Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism & related disorders. 15 [PubMed]

Oczkowska A, Lianeri M, Kozubski W, Dorszewska J. (2014). Mutations of PARK genes and a-synuclein and Parkin concentrations in Parkinson's disease A Synopsis of Parkinson's Disease.

Parkinson J. (2002). An essay on the shaking palsy. 1817. The Journal of neuropsychiatry and clinical neurosciences. 14 [PubMed]

Perez RG et al. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22 [PubMed]

Ramanan VK, Saykin AJ. (2013). Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. American journal of neurodegenerative disease. 2 [PubMed]

Rao RV, Bredesen DE. (2004). Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Current opinion in cell biology. 16 [PubMed]

Sahay S et al. (2015). Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of a-synuclein. The Journal of biological chemistry. 290 [PubMed]

Sass MB, Lorenz AN, Green RL, Coleman RA. (2009). A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. Journal of neuroscience methods. 178 [PubMed]

Sato S, Cerny RL, Buescher JL, Ikezu T. (2006). Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of neurochemistry. 98 [PubMed]

Schapira AH. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson's disease. The Lancet. Neurology. 7 [PubMed]

Schapira AH et al. (1990). Mitochondrial complex I deficiency in Parkinson's disease. Journal of neurochemistry. 54 [PubMed]

Sharpless NS et al. (1981). Free and conjugated dopamine in human ventricular fluid. Brain research. 217 [PubMed]

Shulman JM, De Jager PL, Feany MB. (2011). Parkinson's disease: genetics and pathogenesis. Annual review of pathology. 6 [PubMed]

Sidhu A, Wersinger C, Moussa CE, Vernier P. (2004). The role of alpha-synuclein in both neuroprotection and neurodegeneration. Annals of the New York Academy of Sciences. 1035 [PubMed]

Singh Dolt K, Hammachi F, Kunath T. (2017). Modeling Parkinson's disease with induced pluripotent stem cells harboring a-synuclein mutations. Brain pathology (Zurich, Switzerland). 27 [PubMed]

Sipos I, Tretter L, Adam-Vizi V. (2003). Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. Journal of neurochemistry. 84 [PubMed]

Speed NK. (2010). The role of insulin signaling on dopamine transporter trafficking. Doctoral dissertation, Vanderbitt University, Nashville, TN.

Sulzer D. (2001). alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nature medicine. 7 [PubMed]

Tretter L, Adam-Vizi V. (2004). Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. The Journal of neuroscience : the official journal of the Society for Neuroscience. 24 [PubMed]

Wellstead P, Cloutier M. (2009). A systems approach to Parkinson's disease.

Wenya W. (2011). Inhibition of Tau phosphorylation as a potential strategy in treatment of Parkinson's disease Towards New Therapies for Parkinson's Disease.

Werner-Allen JW, DuMond JF, Levine RL, Bax A. (2016). Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of a-Synuclein. Angewandte Chemie (International ed. in English). 55 [PubMed]

Wersinger C, Prou D, Vernier P, Niznik HB, Sidhu A. (2003). Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Molecular and cellular neurosciences. 24 [PubMed]

Wersinger C, Sidhu A. (2003). Attenuation of dopamine transporter activity by alpha-synuclein. Neuroscience letters. 340 [PubMed]

Yamamori H et al. (2007). Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neuroscience letters. 418 [PubMed]

Yeager MP, Coleman RA. (2010). In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease. Journal of neuroscience methods. 188 [PubMed]

Zhang Y et al. (2000). Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences of the United States of America. 97 [PubMed]

This website requires cookies and limited processing of your personal data in order to function. By continuing to browse or otherwise use this site, you are agreeing to this use. See our Privacy policy and how to cite and terms of use.